Keyword Analysis & Research: mmae
Keyword Research: People who searched mmae also searched
Search Results related to mmae on Search Engine
-
Monomethyl auristatin E - Wikipedia
https://en.wikipedia.org/wiki/Monomethyl_auristatin_E
Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. I… See more
DA: 99 PA: 64 MOZ Rank: 98
-
Monomethyl auristatin antibody and peptide drug conjugates for …
https://www.nature.com/articles/s41467-022-31601-z
WEBJul 5, 2022 · Tumor-directed antibodies and peptides conjugated to radiosensitizing monomethyl auristatin E (MMAE) specifically produce CD8 T cell dependent durable …
DA: 67 PA: 59 MOZ Rank: 27
-
Monomethyl auristatin E | C39H67N5O7 | CID …
https://pubchem.ncbi.nlm.nih.gov/compound/Monomethyl-auristatin-E
WEB2024-04-06. Description. Monomethyl Auristatin E is a dolastatin-10 peptide derivative with potent antimitotic activity and potential antineoplastic activity as part of an antibody-drug conjugate (ADC). Monomethyl auristatin E ( …
DA: 93 PA: 22 MOZ Rank: 72
-
Antibody-drug conjugates with dual payloads for combating
https://www.nature.com/articles/s41467-021-23793-7
WEBJun 10, 2021 · Dual conjugation of MMAE and MMAF was selected to make ADCs capable of killing a broad range of breast cancer cells. MMAE is cell membrane-permeable and … Author: Chisato M. Yamazaki, Aiko Yamaguchi, Yasuaki Anami, Wei Xiong, Yoshihiro Otani, Jangsoon Lee, Naoto ... Publish Year: 2021
Author: Chisato M. Yamazaki, Aiko Yamaguchi, Yasuaki Anami, Wei Xiong, Yoshihiro Otani, Jangsoon Lee, Naoto ...
Publish Year: 2021
DA: 59 PA: 45 MOZ Rank: 90
-
Whole-Body Pharmacokinetics and Physiologically Based …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004929/
WEBMar 23, 2021 · Monomethyl auristatin E (MMAE) is one of the most commonly used payloads to make ADCs, and Adcetris ® (brentuximab vedotin), Padcev ® (enfortumab … Author: Hsuan Ping Chang, Yuen Kiu Cheung, Dhaval K Shah DOI: 10.3390/jcm10061332 Publish Year: 2021 Publication: J Clin Med. 2021 Mar; 10(6): 1332.
Author: Hsuan Ping Chang, Yuen Kiu Cheung, Dhaval K Shah
DOI: 10.3390/jcm10061332
Publish Year: 2021
Publication: J Clin Med. 2021 Mar; 10(6): 1332.
DA: 90 PA: 39 MOZ Rank: 39
-
New insight on the structural features of the cytotoxic auristatins
https://www.nature.com/articles/s41598-017-15674-1
WEBNov 21, 2017 · The auristatins monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) appear as the cytotoxic drug in almost half of the state-of-the-art ADCs on the …
DA: 10 PA: 64 MOZ Rank: 36
-
Monomethyl Auristatin E - an overview | ScienceDirect Topics
https://www.sciencedirect.com/topics/neuroscience/monomethyl-auristatin-e
WEBMonomethyl auristatin E (MMAE) is a synthetic antimitotic agent used as a warhead in antibody-drug conjugates (ADCs) for cancer therapy. Learn about its structure, …
DA: 81 PA: 55 MOZ Rank: 79
-
Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609178/
WEBOct 7, 2022 · Collectively, this study provides a promising approach for safe and effective chemotherapy via MMAE-based prodrug nanoparticles, which may open new avenues …
DA: 94 PA: 88 MOZ Rank: 60
-
Clinical Pharmacology of the Antibody-Drug Conjugate ... - PubMed
https://pubmed.ncbi.nlm.nih.gov/38609704/
WEBPharmacokinetics (PK) of enfortumab vedotin (antibody-drug conjugate and total antibody) and free MMAE were evaluated in five clinical trials of patients with locally advanced or …
DA: 70 PA: 16 MOZ Rank: 43
